Laboratory Evaluation of the VISITECT Advanced Disease Semiquantitative Point-of-Care CD4 Test. (15th December 2022)

• Record Type: Journal Article
• Authors: Lechiile, Kwana; Leeme, Tshepo B.; Tenforde, Mark W.; Bapabi, Mbabi; Magwenzi, Julita; Maithamako, Oitshepile; Mulenga, Fredah; Mohammed, Terence; Ngidi, Julia; Mokomane, Margaret; Lawrence, David S.; Mine, Madisa; Jarvis, Joseph N.
• Is Part Of: Journal of acquired immune deficiency syndromes. Volume 91:Number 5(2022)
• Page Start: 502
• Page End: 507
• Publication Date: 2022-12-15
• Subjects: HIV -- AIDS -- CD4 count -- point-of-care -- advanced HIV disease; AIDS (Disease) -- Periodicals; Acquired Immunodeficiency Syndrome -- Periodicals; AIDS (Disease); Periodicals; 616.9792005
• DOI: 10.1097/QAI.0000000000003092
• Languages: English
• ISSNs: 1525-4135

Abstract

Abstract : Background: Advanced HIV disease (AHD; CD4 counts <200 cells/µL) remains common in many low- and middle-income settings. An instrument-free point-of-care test to rapidly identify patients with AHD would facilitate implementation of the World Health Organization (WHO) recommended package of care. We performed a laboratory-based validation study to evaluate the performance of the VISITECT CD4 Advanced Disease assay in Botswana. Setting: A laboratory validation study. Methods: Venous blood samples from people living with HIV having baseline CD4 testing in Gaborone, Botswana, underwent routine testing using flow cytometry, followed by testing with the VISITECT CD4 Advanced Disease assay by a laboratory scientist blinded to the flow cytometry result with a visual read to determine whether the CD4 count was below 200 cells/µL. A second independent investigator conducted a visual read blinded to the results of flow cytometry and the initial visual read. The sensitivity and specificity of the VISITECT for detection of AHD were determined using flow cytometry as a reference standard, and interrater agreement in VISITECT visual reads assessed. Results: One thousand fifty-three samples were included in the analysis. The VISITECT test correctly identified 112/119 samples as having a CD4 count <200 cells/µL, giving a sensitivity of 94.1% (95% confidence interval: 88.3% to 97.6%) and specificity of 85.9% (95% confidence interval: 83.5% to 88.0%) compared with flow cytometry. Interrater agreement between the 2 independent readers was 97.5%, Kappa 0.92 ( P < 0.001). Conclusions: The VISITECT CD4 advanced disease reliably identified individuals with low CD4 counts and could facilitate implementation of the WHO recommended package of interventions for AHD.